Gilead Agrees to Buy PepStar’s IL-23R Inhibitor Program for $1.28 Billion Upfront

Bitget2026/10/22 20:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gilead Sciences agreed to acquire PepStar Therapeutics’ oral IL-23R inhibitor program for $1.28 billion in upfront cash, payable at closing.
The deal includes worldwide rights to lead asset HCXT-2001, a clinical-stage oral treatment with potential applications in inflammatory bowel disease.
Closing is expected in the fourth quarter of 2026, subject to customary conditions.
The transaction is expected to reduce GAAP and non-GAAP earnings per share by approximately $0.79 to $0.83 in the quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610221605BIZWIRE_USPR_____20261022_BW181871) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gilead Agrees to Buy PepStar’s IL-23R Inhibitor Program for $1.28 Billion Upfront

You may also like

Crypto prices